The second wave in kinase cancer drugs
Article Abstract:
The US Food and Drug Association (FDA) gave Onyx Pharmaceuticals approval of a protein kinase inhibitor for treating cancer and two more awaiting almost FDA approval with at least 40 in clinical trials makes kinase the second most popular drug target class in the pharmaceutical and biotech industries. The drugs, however, in most parts have neither met the expectations of the doctors who prescribed them nor the hopes of the patients who need them.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2006
User Contributions:
Comment about this article or add new information about this topic:
Conflicting signals on US accelerated approvals
Article Abstract:
A study described that as London-based AstraZeneca disclosed results in December 2004 from phase 3 study showing its cancer drug Iressa did not produce a significant survival advantage over placebo, it has become the poster child for companies with accelerated approval whiplash. However, in June 2005, the pharmaceutical industry agreed to a label change that effectively nulls Iressa's approval.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2005
User Contributions:
Comment about this article or add new information about this topic:
Knockout drug screens
Article Abstract:
Researchers utilize a top-down drug screening strategy to show how compounds containing gene selective properties can be identified by isogenic cell lines that have a difference of just one genetic change.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2001
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Chips advance but cost constraints remain. US patent office strategic plan may penalize biotechs. Racially defined haplotype project debated
- Abstracts: Sailing towards troubled waters. Changing Signals on the Kursk Lift. The Zumwalt-class destroyers
- Abstracts: Remaining relevant. Continental drift. Setting the tone
- Abstracts: The road to empowerment. Trusting your instincts. Sites for sore eyes
- Abstracts: Three back Centrica. Centrica. National Grid